Skip to main content

Table 2 Patient characteristics

From: Quality of life after definitive linear accelerator-based stereotactic radiotherapy for prostate cancer: a longitudinal study

Factors N %
Total 439 100
Age (years old)
 Median (range) 73 (33–92)
 Quartile 68 and 78
iPSA (ng/mL)
 Median (range) 9.2 (1.6–24.0)
 Quartile 6.3 and 14.7
Clinical T-stage
 T1c 84 19.1
 T2a 208 47.4
 T2b 20 4.6
 T2c 61 13.9
 T3a 46 10.5
 T3b 14 3.2
 T4 6 1.4
Gleason score group
 Group 1 46 10.5
 Group 2 121 27.6
 Group 3 117 26.7
 Group 4 82 18.7
 Group 5 73 16.6
Risk group
 Low 21 4.8
 Intermediate-low 84 19.1
 Intermediate-high 149 33.9
 High 112 25.5
 Ver-high 73 16.6
Hormonal therapy
 None 98 22.3
 Short term 183 41.7
 Long term 158 36.0
RT total dose
 36.25 Gy 239 54.4
 40 Gy 187 42.6
 42.5 Gy 13 3.0
  1. PSA prostate-specific antigen, RT radiation therapy